Abatacept: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PHARMAC (New Zealand) and SMC (Scotland), among others, recommended or restricted abatacept, while AWMSG (Wales) and CIPM (Spain) did not recommend it.
The file has been open for more than a decade: 18.2 years separate the first record, 22 Jun 2006 at TLV (Sweden), from the most recent, 22 Sep 2024 at NYE METODER (Norway).
CONITEC (Brazil) changed its position: recommended on 11 Sep 2012, not recommended by 1 Dec 2016.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for abatacept, 2 submissions were never made and 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The programme is broad: 11 distinct indication wordings are recorded for abatacept by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 34 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess abatacept, on 22 Jun 2006; NYE METODER (Norway) did not open a file until 22 Sep 2024 — an unusually long tail of 18.2 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 15 years in total.
7 of the 10 agencies here assessed abatacept more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for abatacept.
The full ledger for abatacept reads 15 recommended, 6 not recommended, 3 other and 2 non-submission, with 8 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 22 Sep 2024 | Alene eller i kombinasjon med metotreksat (MTX) til behandling av aktiv psoriasisartritt (PsA) hos voksne pasienter som … | decision recorded | source |
| HAS (France) | 6 Oct 2021 | Re-assessment following post-listing study results | SMR substantial | source |
| CIPM (Spain) | 15 Sep 2020 | Indicaciones terapéuticas autorizadas: Artritis reumatoide ORENCIA, en combinación con metotrexato, está indicado para: … | not financed by the SNS · art. 92 e | source |
| NICE (England) | 13 Mar 2019 | NICE TA568 | terminated appraisal | source |
| AWMSG (Wales) | 10 Aug 2017 | Alone or in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients … | excluded, NICE appraised | source |
29 further decisions for abatacept, across 8 agencies, are not shown here. They link to 21 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 34 decisions for abatacept from 10 agencies, 2006 to 2024. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.